The implant is composed of plant-based caboxymethyl cellulose that provides support to hold the soft nasal tissue in place and pressure to prevent bleeding.
The Nasastent eventually converts into a hydrocolloidal gel after absorbing nasal fluid and drains from the patient naturally, the London-based company said.
“Smith & Nephew is committed to innovation that improves both the patient and the physician experience and is proud to offer pioneering technologies such as Nasastent within our leading specialist ENT surgical portfolio,” ENT and gynecology general manager Mira Sahney said in prepared remarks.
The Nasastent is 6-times stronger than its leading competitor and provides “significantly higher tissue separation force over a variety of simulated nasal cavity gaps,” according to Smith & Nephew.
In July, Smith & Nephew said it acquired Russia’s DeOst group, which makes and distributes trauma and orthopedic devices, for an undisclosed amount.
DeOst has distributed the British healthcare giant’s products in Russia since 2009, Smith & Nephew said. Smith & Nephew said it’s taking on about 350 DeOst employees in the deal.